Premium
Hypoxia and anaemia in head and neck squamous cell carcinoma – mechanisms of therapy failure and provision of new therapeutic targets
Author(s) -
Winter S.C.A.,
Corbridge R.J.,
Cox G.J.,
Harris A.L.
Publication year - 2005
Publication title -
clinical otolaryngology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.914
H-Index - 68
eISSN - 1749-4486
pISSN - 1749-4478
DOI - 10.1111/j.1365-2273.2004.00946.x
Subject(s) - medicine , hypoxia (environmental) , head and neck squamous cell carcinoma , erythropoiesis , angiogenesis , cancer research , basal cell , head and neck , oncology , apoptosis , head and neck cancer , radiation therapy , anemia , surgery , oxygen , biology , chemistry , organic chemistry , biochemistry
Keypoints • Head and neck squamous cell carcinoma (HNSCC) represents the sixth most common tumour worldwide. • Tumour hypoxia and anaemia are both independent prognostic indicators of disease free and overall survival in solid tumours, including HNSCC. • Hypoxia promotes tumour progression through the hypoxia inducible factor 1 pathway (HIF‐1), upregulating factors that control angiogenesis, glycoloysis, pH regulation, erythropoiesis and apoptosis. • Oxygen delivery to tumours is influenced by the oxygen carrying capacity of the blood, and therefore anaemia may promote tumour hypoxia. • Targeting the HIF‐1 pathway and anaemia represent potential therapeutic targets in HNSCC and other solid tumours.